Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation

Abstract

Greater cancer risk is not observed in IMNM vs controls. Cancer screening in IMNM should be individualized based on age-personal and family history, including consideration of FDG-PET/CT. Immune-treatment response did not differ with cancer.